Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cero Therapeutics Holdings Inc. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are being handled by 3 distinct examiners. These examiners are distributed across 2 distinct art units, indicating some overlap in the technical groups reviewing the company's applications. For a practitioner, this suggests that while the examiners are different, their work is concentrated within 2 specialized units at the patent office.
CANELLA, KAREN A is the busiest examiner for the portfolio, overseeing 1 pending office action. Given the 3 pending office actions and multiple distinct examiners, the busiest examiner is responsible for 1 action. The use of 2 distinct art units for the actions suggests that at least some of the examiners are working within the same specialized unit. This environment requires a strategy that balances the individual preferences of the examiners with the shared standards of the units they represent to ensure consistent prosecution outcomes.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CANELLA, KAREN A | 1 | 62.2% | +32.8% |
| LUNDE, GRACE HENRY | 1 | 63.0% | +38.9% |
| DRISCOLL, MAUREEN VARINA | 1 | 63.7% | +40.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18041195 | CHIMERIC TIM RECEPTORS AND USES THEREOF | DRISCOLL, MAUREEN VARINA | 41d |
| 18292782 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | CANELLA, KAREN A | — |
| 18041200 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE | LUNDE, GRACE HENRY | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18292782 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | CANELLA, KAREN A | — | §112 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18041200 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE | LUNDE, GRACE HENRY | 1641 | §112DP | Final Rejection | — | Pending | Feb 09, 2023 |
| 18041195 | CHIMERIC TIM RECEPTORS AND USES THEREOF | DRISCOLL, MAUREEN VARINA | 1644 | §103Other | Final Rejection | 41d | Pending | Feb 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial